Brief: Acer Therapeutics And Relief Therapeutics Announce FDA Acceptance For NDA For Urea Cycle Disorders Treatment
06/10/2021 13:49
Oct 6 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS AND RELIEF THERAPEUTICS ANNOUNCE FDA
ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR ACER-001 TO
TREAT UREA CYCLE DISORDERS
* ACER THERAPEUTICS AND RELIEF THERAPEUTICS ANNOUNCE FDA
ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR ACER-001 TO
TREAT UREA CYCLE DISORDERS
* ACER THERAPEUTICS INC - FDA HAS ASSIGNED A PRESCRIPTION
DRUG
USER FEE ACT (PDUFA) TARGET ACTION DATE OF JUNE 5, 2022
Source text for Eikon: ID:nGNX2873nZ
Further company coverage: ACER.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31